Click here to view Chinese version
Latest Share Price
26.00
0.00
26.00
0.00
Get the Flash Player to see this player.
Click here to view our new company videoPower of
Plants
Plants have long been
a reliable source of new
anti-infective and
anti-cancer
drugs. Using medicines
identified in China as a starting
point,
Phynova develops
Western pharmaceutical drugs
protected by the Company's own
intellectual property.
Drug Candidates
PYN17 HEPATITIS C
Chronic Hepatitis C
PYN22 NAFLD
For Non Alcoholic Fatty Liver Disease ('NAFLD')
PYN9 POI
For Post Operative Ileus
PYN6 MRSA
For MRSA and Acne
PYN18 HEPATITIS C
Hepatitis C Virus and Dengue
PYN7 CANCER
For Cancer
News
New strategic focus, management and board changes to position the Company for future growth and trading update
22 September 2008 Phynova Group PLC ("Phynova" or the "Company") New strategic focus, ...
Phynova Announces Notification of Patent Allowance
Phynova Group PLC 8 July 2008 ("Phynova" or the "Company") Phynova Announces Notificati...
Phynova Announces Half-Yearly Results for Period Ended 31 March 2008
27 June 2008 Phynova Group PLC ("Phynova" or the "Company") PHYNOVA ANNOUNCES HALF-YEA...
Pipeline
Phynova has identified a number of Drug Candidates in the fields of anti-virals, anti-microbials, anti-inflammatories and oncology. At present, it is concentrating its development efforts on six of these: PYN17, PYN22, PYN9, PYN6, PYN18 and PYN7.